Site Map
- Home
- Efficacy
- MMDs: Ph 3 EM Months 4 to 6
- MMDs: Ph 2 EM Year 5
- Response Rates: ≥50% Response
- Response Rates: ≥75% Response
- Prior Preventives: Monthly Migraine Days
- Prior Preventives: Subgroup Population
- Safety
- Pooled Pivotal Studies
- Ph 3 EM ATP at Year 1
- Ph 2 EM at Month 3 and Year 5
- Dosing
- Resources to Start Aimovig®
- AHS Guidance for Treatment Course
- COVID-19 FAQs
- Indication
- Prescribing Info
- Prescribing Information (English)
- Información de Prescripcion (Spanish)
- Patient Product Information (English)
- Información Para el Paciente (Spanish)
- Instructions for Use 70 mg/mL (English)
- Instrucciones de Use 70 mg/mL (Spanish)
- Instructions for Use 140 mg/mL (English)
- Instrucciones de Use 140 mg/mL (Spanish)
- Visit Patient Site
- Amgen
- Novartis
- Contact
- Privacy Statement
- Terms of Use
- Ad Choices